Biohaven Pharmaceutical Holding Company Ltd.
-
Ticker
BHVN
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 501-1000 Employees
- Based in New Haven, Connecticut
Biohaven is a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases. Biohaven's neuroinnovation portfolio includes FDA-approved NURTECâ„¢ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates
…More across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and myeloperoxidase (MPO) inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
REPORT RATINGS
5.0 / 5.0 (1)
Biohaven Pharmaceutical Holding Company Ltd. reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Biohaven Pharmaceutical Holding Company Ltd.
Most Recent Responsibility Report
MOST RECENT
2023 Sustainability Report
Report Locked. Biohaven Pharmaceutical Holding Company Ltd. has reached its limit for free report views.
Our service enables potential investors to review the most recent and archived Biohaven Pharmaceutical Holding Company Ltd. Sustainability Report, Biohaven Pharmaceutical Holding Company Ltd. Corporate Social Responsibility Report, Biohaven Pharmaceutical Holding Company Ltd. CSR Report, Biohaven Pharmaceutical Holding Company Ltd. Corporate Responsibility, Biohaven Pharmaceutical Holding Company Ltd. CR Report, Biohaven Pharmaceutical Holding Company Ltd. Citizenship Report, Biohaven Pharmaceutical Holding Company Ltd. ESG Report, and Biohaven Pharmaceutical Holding Company Ltd. Environmental Report online.